Published in Medical Letter on the CDC and FDA, July 24th, 2005
Levemir is a long-acting form of insulin that provides up to a 24-hour duration of action and has been shown to cause little weight change, according to the company.
"Experts agree there is a significant need for consistent good control of patients' glucose levels, which is associated with a reduced risk of diabetes complications," said Peter Aurup, MD, vice president of the clinical development, medical, and regulatory affairs department. "The...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.